Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma

British Journal of Haematology

Volumn 143, Issue 1, 2008, Pages 148-150

  Colson, Philippe ^a,b   Borentain, Patrick ^c   Coso, Diane ^d   Chabannon, Christian ^d   Tamalet, Catherine ^a,b   Gérolami, René ^c  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d INSTITUT PAOLI CALMETTES   (France)

Author keywords

Chemotherapy; Entecavir; Haematopoietic stem cell transplantation; Hepatitis B virus; Lymphoma; Reactivation

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ENTECAVIR; ETOPOSIDE; HEPATITIS B VACCINE; LAMIVUDINE; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; HEPATITIS B; HUMAN; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY; STEM CELL TRANSPLANTATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; GUANINE; HEPATITIS B VIRUS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; VIRUS ACTIVATION;

EID: 51249107058     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07318.x     Document Type: Letter

References (8)

1. Gish, R.G., Lok, A.S., Chang, T.T., de Man, R.A., Gadano, A., Sollano, J., Han, K.H., Chao, Y.C., Lee, S.D., Harris, M., Yang, J., Colonno, R. Brett-Smith, H. (2007) Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology, 133, 1437 1444.
2. Lai, C.L., Shouval, D., Lok, A.S., Chang, T.T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R.C., Cross, A., Colonno, R. Fernandes, L. (2006) BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine, 354, 1011 1020.
3. Lalazar, G., Rund, D. Shouval, D. (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. British Journal of Haematology, 136, 699 712.
4. Law, J.K., Ali, J.A., Harrigan, P.R., Sherlock, C.H., Savage, K.J. Yoshida, E.M. (2006) Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. American Journal of Hematology, 81, 969 972.
5. Liaw, Y.F., Leung, N.W., Chang, T.T., Guan, R., Tai, D.I., Ng, K.Y., Chien, R.N., Dent, J., Roman, L., Edmundson, S. Lai, C.L. (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology, 119, 172 180.
6. Milpied, N., Deconinck, E., Gaillard, F., Delwail, V., Foussard, C., Berthou, C., Gressin, R., Lucas, V., Colombat, P. Harousseau, J.L., Groupe Ouest-Est des Leucémies et des autres maladies du sang (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. New England Journal of Medicine, 350, 1287 1295.
7. Sherman, M., Yurdaydin, C., Sollano, J., Silva, M., Liaw, Y.F., Cianciara, J., Boron-Kaczmarska, A., Martin, P., Goodman, Z., Colonno, R., Cross, A., Denisky, G., Kreter, B. Hindes, R. (2006) AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology, 130, 2039 2049.
8. Yeo, W. Johnson, P.J. (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 43, 209 220.